FCCC LOGO Faculty Publications
Liu T , Kan XF , Ma C , Chen LL , Cheng TT , Zou ZW , Li Y , Cao FJ , Zhang WJ , Yao J , Li PD
GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma
Tumour Biol. 2017 Jun;39(6) :1010428317700410
Back to previous list
Abstract
Glutathione peroxidase 2 has important role of tumor progression in lots of carcinomas, yet little is known about the prognosis of glutathione peroxidase 2 in hepatocellular carcinoma. Glutathione peroxidase 2 expression was assessed by immunohistochemistry in hepatocellular carcinoma tissues. The association between glutathione peroxidase 2 expression with clinicopathological/prognostic value was examined. Glutathione peroxidase 2 overexpression was correlated with alpha-fetoprotein level, larger tumor, BCLC stage, and tumor recurrence. Kaplan-Meier analysis showed that glutathione peroxidase 2 was an independent predictor for overall survival and time to recurrence. glutathione peroxidase 2 overexpression was correlated with poor prognosis in patient subgroups stratified by tumor size, differentiation, tumor-node-metastasis, and BCLC stage. Moreover, stratified analysis showed that tumor-node-metastasis stage-I patients with high glutathione peroxidase 2 expression had poor prognosis than those with low glutathione peroxidase 2 expression. Additionally, combination of glutathione peroxidase 2 and serum alpha-fetoprotein was correlated with prognosis in hepatocellular carcinoma. In conclusion, glutathione peroxidase 2 overexpression contributes to poor prognosis of hepatocellular carcinoma patients and helps to identify the high-risk hepatocellular carcinoma patients.
Notes
1423-0380 Liu, Ting Kan, Xue-Feng Ma, Charlie Chen, Li-Li Cheng, Tian-Tian Zou, Zhen-Wei Li, Yong Cao, Feng-Jun Zhang, Wen-Jie Yao, Jing Li, Pin-Dong Journal Article United States Tumour Biol. 2017 Jun;39(6):1010428317700410. doi: 10.1177/1010428317700410.